Pharmazz
Willowbrook, USA· Est.
Innovative biotech delivering endothelin‑based drugs for critical care and neuroscience.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $25M
AI Company Overview
Innovative biotech delivering endothelin‑based drugs for critical care and neuroscience.
NeuroscienceCardiovascularCritical Care
Technology Platform
Endothelin receptor modulation (ET‑A and ET‑B agonists) delivering vascular tone regulation and neuro‑protective effects for acute and chronic indications.
Opportunities
Successful Phase 3 results for Sovateltide could unlock a multi‑billion‑dollar stroke market, while Centhaquine’s approved status in India offers a platform for global expansion into trauma and sepsis care.
Risk Factors
Clinical trial failures, regulatory delays outside India, and competition from established stroke and shock therapies could impede commercialization.
Competitive Landscape
Key competitors include tPA, mechanical thrombectomy for stroke and conventional vasopressors for shock; Pharmazz differentiates via endothelin‑based mechanisms that target both vascular tone and neuro‑protection.